Evogene Analyst Ratings
Evogene Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/21/2023 | 417.24% | Roth MKM | $1 → $6 | Maintains | Buy |
| 05/02/2023 | 72.41% | Lake Street | → $2 | Initiates Coverage On | → Buy |
| 09/12/2022 | 589.66% | Aegis Capital | $10 → $8 | Maintains | Buy |
| 10/08/2021 | 503.45% | Roth Capital | → $7 | Initiates Coverage On | → Buy |
| 07/29/2021 | 762.07% | Aegis Capital | → $10 | Initiates Coverage On | → Buy |
| 12/01/2020 | 675.86% | Cantor Fitzgerald | → $9 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 07/21/2023 | 417.24% | Roth MKM | $1 → 6 美元 | 维护 | 购买 |
| 05/02/2023 | 72.41% | 湖街 | → 2 美元 | 启动覆盖开启 | → 购买 |
| 2022 年 12 月 9 日 | 589.66% | 宙斯盾资本 | 10 美元 → 8 美元 | 维护 | 购买 |
| 2021 年 8 月 10 日 | 503.45% | 罗斯资本 | → 7 美元 | 启动覆盖开启 | → 购买 |
| 2021 年 7 月 29 日 | 762.07% | 宙斯盾资本 | → 10 美元 | 启动覆盖开启 | → 购买 |
| 12/01/2020 | 675.86% | 坎托·菲茨杰拉德 | → 9 美元 | 启动覆盖开启 | → 超重 |
What is the target price for Evogene (EVGN)?
Evogene（EVGN）的目标价格是多少？
The latest price target for Evogene (NASDAQ: EVGN) was reported by Roth MKM on July 21, 2023. The analyst firm set a price target for $6.00 expecting EVGN to rise to within 12 months (a possible 417.24% upside). 3 analyst firms have reported ratings in the last year.
Roth MKM于2023年7月21日公布了Evogene（纳斯达克股票代码：EVGN）的最新目标股价。这家分析公司将目标股价定为6.00美元，预计EVGN将在12个月内升至6美元（可能上涨417.24％）。去年有3家分析公司公布了评级。
What is the most recent analyst rating for Evogene (EVGN)?
分析师对Evogene（EVGN）的最新评级是多少？
The latest analyst rating for Evogene (NASDAQ: EVGN) was provided by Roth MKM, and Evogene maintained their buy rating.
Evogene（纳斯达克股票代码：EVGN）的最新分析师评级由Roth MKM提供，Evogene维持买入评级。
When is the next analyst rating going to be posted or updated for Evogene (EVGN)?
Evogene（EVGN）的下一个分析师评级何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Evogene, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Evogene was filed on July 21, 2023 so you should expect the next rating to be made available sometime around July 21, 2024.
分析师在进行了广泛的研究（包括浏览公开财务报表、与Evogene的高管和客户交谈以及听取财报电话会议）后得出股票评级。大多数分析师每三个月进行一次评级，因此每家公司每年应该获得4个评级。Evogene的最后一次评级是在2023年7月21日提交的，因此您应该预计下一个评级将在2024年7月21日左右公布。
Is the Analyst Rating Evogene (EVGN) correct?
分析师对Evogene (EVGN) 的评级是否正确？
While ratings are subjective and will change, the latest Evogene (EVGN) rating was a maintained with a price target of $1.00 to $6.00. The current price Evogene (EVGN) is trading at is $1.16, which is within the analyst's predicted range.
虽然评级是主观的，会发生变化，但最新的Evogene（EVGN）评级维持不变，目标股价为1.00美元至6.00美元。Evogene（EVGN）目前的交易价格为1.16美元，在分析师的预测区间内。